Story by John Lauerman • Yesterday 3:21 PM
(Bloomberg) — Merck & Co.’s Covid-19 pill is giving rise to new mutations of the virus in some patients, according to a study that underscores the risk of trying to intentionally alter the pathogen’s genetic code.
BARI, ITALY – JANUARY 11: Doctor holds in her hands the Lagevrio pill, Molnupiravir indicator for the treatment of Covid 19 on January 11, 2022 in Bari, Italy. The European Medicines Agency (EMA) announced in a press release published on January 10, that it will examine application for marketing authorization for the antiviral pill developed by Pfizer. Both Pfizer and Merck antiviral drugs have been hailed as potentially revolutionary in the fight against Covid-19, as studies show they reduce the risk of hospitalization and death in patients at increased risk of developing a severe form of the disease. (Photo by Donato Fasano/Getty Images)© Photographer: Donato Fasano/Getty Images
Some researchers worry the drug may create more contagious or health-threatening variations of Covid, which has killed more than 6.8 million people globally over the past three years.
Mutations linked to the use of Merck’s pill, Lagevrio, have been identified in viral samples taken from dozens of patients, according to a preprint study from researchers in the US and at the Francis Crick Institute, Imperial College London and other UK institutions.
The drug-linked mutations of the virus haven’t been shown to be more immune-evasive or lethal yet, according to the study published Friday without peer review on the medRxiv website. But their very existence highlights what some scientists say are potential risks in wider use of the drug, which was recently cleared in China.
Lagevrio works by creating mutations in the Covid genome that prevent the virus from replicating in the body, reducing the chances it will cause severe illness. Some scientists had warned before it was authorized in late 2021 that by virtue of how it works, the drug could give rise to mutations that could turn out to be problematic. The preprint paper has reawakened those worries about the Merck drug.
“There’s always been this underlying concern that it could contribute to a problem generating new variants,” said Jonathan Li, a virologist at Harvard Medical School and Brigham and Women’s Hospital in Boston. “This has largely been hypothetical, but this preprint validates a lot of those concerns.”
Merck Response
Merck disputes the view that its drug is causing problematic variants.
“There is no evidence to indicate that any antiviral agent has contributed to the emergence of circulating variants,” Merck spokesman Robert Josephson said in an email in response to questions about the study. “Based on available data we do not believe that Lagevrio (molnupiravir) is likely to contribute to the development of new meaningful coronavirus variants.”
He said new mutations have emerged over the course of the pandemic due to the virus spreading uncontrollably and Lagevrio can form an important part of the solution, he said. Merck pointed to research done in animals that showed its drug didn’t cause mutations.
The study authors assume the mutations were associated with molnupiravir treatment, but don’t have direct proof that the mutations arose in patients who took their drug, Josephson said in a follow-up email. Instead, the researchers drew their conclusions from “circumstantial associations between viral sequence origin and timeframe of sequence collection in countries where molnupiravir is available,” Josephson said.
Merck fell as much as 1.2% in New York Wednesday, recovering some losses to close down 0.4%.
The US Food and Drug Administration, which authorized Lagevrio in late 2021, said it doesn’t comment on third-party research and works with Covid drugmakers to assess their products’ activity against variants.
Leave a Reply